Phase-In of Manufacturer Discounts for Life-Saving Plasma Drugs in Medicare.
This law changes how expensive, life-saving plasma-derived drugs are covered under the Medicare Part D insurance program. It introduces a multi-year phase-in schedule for the discounts manufacturers must provide for these specific medications. This gradual approach aims to ensure continued access to these critical therapies while adjusting the financial responsibilities of drug makers.
Key points
Establishes a special, multi-year discount schedule for manufacturers of plasma-derived products covered by Medicare Part D, starting in 2026.
The manufacturer's required contribution (discount) for these drugs will gradually decrease from 99% in 2026 to 80% or 90% (depending on the patient's spending phase) in subsequent years.
The change applies only to biological products derived from human blood or plasma that were already on the market as of August 2022.
Introduced
Citizen Poll